Non Surgical Management for Uterine Residua After Pregnancy Termination, Abortion or Delivery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to find out whether conservative treatment - expectant management or medical therapy using misoprostol is beneficial in the case of uterine residua, and which treatment is better.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dilation and Curettage Versus Operative Hysteroscopy for Missed Abortion

NCT04705324

Spontaneous Abortion Missed Abortion Intrauterine Adhesion +1 more

UNKNOWN NA

Management of RPOC After Induced Abortion

NCT04685694

Abortion Induced Complicated

COMPLETED PHASE4

Misoprostol for Non-Viable Pregnancies

NCT00426491

Abortifacient Agents, Nonsteroidal Abortion, Incomplete Misoprostol +1 more

COMPLETED PHASE3

Intraumbilical Misoprostol in Retained Placenta

NCT01840813

Retained Placenta

COMPLETED PHASE1

Fertility and Obstetric Outcomes After Medical Management Versus Surgical Treatment for First-trimester Miscarriage First-trimester Miscarriage

NCT03570307

Medical; Abortion, Fetus

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Retained products of conception are estimated to occur after approximately 1-6% of pregnancies, probably more often after termination of early pregnancies then after term pregnancy. Complication are abdominal pain, infection, bleeding and for the long term - intrauterine adhesions.Blood clots in the uterine cavity can cause similar complications. The definitive treatment is curettage or hysteroscopy, both of which are carried out under general anesthesia and require an operating theater. Although expectant management and uterotonic drugs are practically used in such situation, they are not described in the literature.This study compare between the outcome of misoprostol treatment and expectant management in the case of intrauterine residua after completion of pregnancy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intra-uterine Residua

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intra-uterine residua. expectant management

The patients in this arm will not get any treatment and be followed up by US examinations

Group Type NO_INTERVENTION

No interventions assigned to this group

Intra-uterine residua. misoprostol

The patients in this arm will be treated with misoprostol at the recruitment day. If there will be sonographic evidence of intra-uterine residua the day after, they'll gat another dose.

Group Type EXPERIMENTAL

misoprostol

Intervention Type DRUG

8oo mcg intravaginal, second dose after one day if there is no response

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

misoprostol

8oo mcg intravaginal, second dose after one day if there is no response

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cytotec

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women with sonographic examination reveals suspicion of intra-uterine residua after completion of pregnancy
* intrauterine cavity, including endometrium, will be at least 15mm

Exclusion Criteria

* the need for emergency surgical treatment (curettage)
* fever - at least 38 celsius degree
* women who had medical termination of pregnancy and the examination is after less then 2 weeks since treatment

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No